Month: May 2023

ATHENS, Greece, May 05, 2023 (GLOBE NEWSWIRE) — Capital Product Partners L.P. (the “Partnership”, “CPLP” or “we” / “us”) (NASDAQ: CPLP), an international owner of ocean-going vessels, today released its financial results for the first quarter ended March 31, 2023. Highlights  Three-month periods ended March 31,  2023 2022 Increase/(Decrease)Revenues $81.0 million $73.4 million 10%Expenses $45.1 million $40.2 million 12%Net Income $10.0 million $25.1 million (60%)Net Income per common unit $0.49 $1.26 (61%)Average number of vessels1 21.4 21.0 2%Operating Surplus2 and Operating Surplus after the quarterly allocation to the capital reserve for the first quarter of 2023 were $36.3 million and $3.0 million, respectively. Announced common unit distribution of $0.15 for the first quarter of 2023. Took delivery...

Company Highlights:Diversified, annuity-based operating platform with a multifamily focus that generates strong distributable earnings and dividends in all cyclesGAAP net income of $0.46 per diluted common share Distributable earnings1 of $0.62 per diluted common share, well in excess of our current dividend, representing a 68% payout ratio Raised cash dividend on common stock to $0.42 per share; a $0.02 per share, or 5% increase, representing an annualized dividend of $1.68 per share Strong liquidity position with ~$785 million in cash and liquidity and ~$560 million of restricted cash in replenishable CLO vehicles with a weighted average cost of 1.64% over benchmark rates2 Agency loan originations of $1.09 billion and a servicing portfolio of ~$28.91 billion, up 3% Structured loan originations of $268.0 million and a portfolio of...

Gurugram, May 04, 2023 (GLOBE NEWSWIRE) — MakeMyTrip Limited to report Fiscal 2023 Fourth Quarter and Full Year Financial & Operating Results on May 16, 2023        Gurugram and New York, May 05, 2023: MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal 2023 fourth quarter and full year financial and operating results before markets open on Tuesday, May 16, 2023. The company will post the release on its Investor Relations website https://investors.makemytrip.com/ and will not be distributing over newswires. A live Zoom Webinar with the senior management team will also be hosted on May 16, 2023 at 7:30 am EDT or 5:00 pm IST through the company’s Investor Relations website at https://investors.makemytrip.com/. To register for the webinar, please follow this link: https://makemytrip.zoom.us/webinar/register/WN_LOAbzEasSrG7FDO1QpFU1w Registered...

Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presented by Takeda at the American Academy of Neurology meetingOV329 Phase 1 trial continues to progress on track with no safety signalsCompany to prioritize development of its clinical small molecule programs; intends to conclude and explore the out-licensing of its genetic medicine programs with Columbia UniversityNEW YORK, May 05, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter...

Atlantica Reports First Quarter 2023 Financial ResultsRevenue for the first quarter of 2023 reached $242.5 million, a 1.5% increase year-over-year on a comparable basis1 and a 2.0% decrease year-over-year. Adjusted EBITDA was $174.2 million for the first quarter of 2023, a 4.0% increase year-over-year on a comparable basis1 and a 0.3% increase year-over-year. Net loss for the first quarter of 2023 attributable to the Company was $11.0 million, compared with a net loss of $12.0 million in the first quarter of 2022. Cash available for distribution (“CAFD”) increased by 12.1% year-over-year up to $61.0 million in the first quarter of 2023 and by 4.6% on a comparable basis2. Quarterly dividend of $0.445 per share approved by the Board of Directors.May 5, 2023 – Atlantica Sustainable Infrastructure plc (NASDAQ: AY) (“Atlantica” or the...

Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%, compared to full year 2022 LOWELL, Mass., May 05, 2023 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2023. Recent HighlightsFirst quarter total revenue (combined product and service revenue) increased 21% to $5.0 million First quarter recurring revenue increased 22% to $3.3 million Placed three new systems and...

Conference Call and Webcast Today at 8:30 a.m. ETAnnounced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the Treatment of ABCA4-Associated Retinopathies Including Stargardt, Retinitis Pigmentosa (RP19), and Cone-Rod Dystrophy 3 (CORD3) Diseases Submitted Multiple Proposals for Federal Funding of Ocugen’s Inhaled Vaccines for COVID-19 and FluMALVERN, Pa., May 05, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported first quarter 2023 financial results along with a general...

TORONTO, May 05, 2023 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2023. Management commentary “Sprott’s Assets Under Management closed at a record high of $25.4 billion as of March 31, 2023,” said Whitney George, CEO of Sprott. “During the quarter, we benefited from approximately $1 billion in net sales in our private strategies and exchange listed products, as well as strong market value appreciation across the majority of our fund products. Looking ahead, we are confident that our positioning in precious metals and energy transition investments will continue to serve our clients and shareholders well as a global realignment of supply chains and critical mineral production unfolds over the coming years.” Financial...

–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population – NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We made substantial progress throughout the first quarter across all areas of our early- and late-stage pipeline,” said John Houston, Ph.D., president and chief executive officer at Arvinas. “Preliminary data from the ongoing Phase 1b combination study of vepdegestrant with...